TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24257717
Drug: Vortioxetine 15
Normalized name: vortioxetine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 15 mg/day
Study: 22100462
Drug: Suspension-exercise-bridge progression
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suspension-exercise-bridge progression
Study: 16138217
Drug: Purple grape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purple grape juice (GJ), 500 ml/day for 14 days
Study: 16138217
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (RW), 250 ml/day for 14 days
Study: 12017006
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release formulation of isosorbide-5-mononitrate (40 mg, qd)
Study: 12017006
Drug: Conventional preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional preparation of isosorbide-5-mononitrate (20 mg, bid)
Study: 2378185
Drug: 500 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 micrograms PGE2 gel
Study: 28080250
Drug: Daclizumab 150
Normalized name: daclizumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab 150 mg subcutaneous
Study: 28080250
Drug: Intramuscular interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular interferon beta-1a 30 µg
Study: 23026182
Drug: Ragweed sublingual
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ragweed sublingual allergy immunotherapy tablet (AIT) at doses of 3, 6, 12, 24, 50, or 100 Amb a 1-U, administered once daily for 28 days
Study: 23026182
Drug: Ragweed sublingual
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ragweed sublingual allergy immunotherapy tablet (AIT)
Study: 19528135
Drug: Methadone Maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone Maintenance Treatment (MMT) alone
Study: 19528135
Drug: Injectable opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable opioids (diacetylmorphine or hydromorphone) plus adjunctive MMT if deemed appropriate
Study: 9722129
Drug: CEE (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE (0.625 mg/day) plus ipriflavone (600 mg/day)
Study: 9722129
Drug: CEE (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE (0.625 mg/day)
Study: 9722129
Drug: ipriflavone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipriflavone (600 mg/day)
Study: 8202971
Drug: Ganglioside GM1
Normalized name: Ganglioside GM1
DrugBank: Ganglioside GM1 (DB16948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganglioside GM1 100 mg intramuscularly daily for 28 days
Study: 2562020
Drug: Histological evaluation
Normalized name: Entamoeba histolytica
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histological evaluation of HA implants
Study: 433813
Drug: Ethanol (9.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (9.3% w/v aqueous alcohol solution)
Study: 31144977
Drug: Beta-alanine (BA)
Normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-alanine (BA) supplementation 30 mg•kg‐1
Study: 26115073
Drug: Multimodal supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal supervised exercise (group exercise classes twice a week for 12 months and once a week for the subsequent 12 months and home exercises)
Study: 23348607
Drug: Tofacitinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib at 5 mg twice daily
Study: 23348607
Drug: Tofacitinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib at 10 mg twice daily
Study: 17653881
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron alone
Study: 14998402
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg day(-1) terbinafine
Study: 14998402
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg day(-1) terbinafine
Study: 11320011
Drug: Verteporfin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verteporfin (6 mg per square meter of body surface area; n = 81)
Study: 8446045
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose administration (IV)
Study: 18194489
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose tolerance test (IVGTT)
Study: 8446045
Drug: Basal molar
Normalized name: Polar Freeze
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal molar proinsulin:insulin ratio (P:I)
Study: 3513687
Drug: Oxymetazoline 0.025%
Normalized name: OXYMETAZOLINE 0.025% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymetazoline 0.025% topical ophthalmic solution
Study: 30497789
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and low molecular weight dextran (Group A)
Study: 30497789
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Group B)
Study: 30497789
Drug: No antithrombotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antithrombotic agent (Group C)
Study: 17481946
Drug: Crataegus extract
Normalized name: crataegus extract
DrugBank: Hawthorn leaf with flower (DB15839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crataegus extract added to standard HF therapy
Study: 12150178
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus 19070-2 and Lactobacillus reuteri DSM 12246, 10(10) colony-forming units of each strain, twice daily for 5 days
Study: 7607715
Drug: Trandolapril 1
Normalized name: trandolapril 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril 1 mg/d
Study: 7607715
Drug: Trandolapril 4
Normalized name: trandolapril 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril 4 mg/d
Study: 7607715
Drug: Trandolapril (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril (various doses)
Study: 31084516
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BR) supplementation (340 mg/d)
Study: 31084516
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) supplementation (<2.5 mg/d)
Study: 21465243
Drug: Sertraline for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline for an average of 24 days
Study: 19733706
Drug: Newly initiated
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Newly initiated statin therapy (36 patients)
Study: 19733706
Drug: Long-term statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-term statin therapy (38 patients)
Study: 19733706
Drug: Newly initiated
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Newly initiated statin therapy
Study: 8501178
Drug: HMG-GRF (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMG-GRF (500 micrograms twice daily)
Study: 3306509
Drug: Doxorubicin 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 40 mg/m2 plus melphalan 0.4 mg/kg every four weeks
Study: 3306509
Drug: Melphalan 1
Normalized name: diluent for melphalan 10 mL INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melphalan 1 mg/kg every four weeks
Study: 29539616
Drug: Resveratrol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (2 sprays of 100 µL/spray in each nostril 3 times/day for 1 month)
Study: 29539616
Drug: Budesonide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (2 sprays of 100 µL/spray in each nostril 3 times/day for 1 month)
Study: 29539616
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 sprays in each nostril 3 times/day for 1 month)
Study: 12773137
Drug: PEG-OB (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-OB (80 mg weekly)
Study: 10574137
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg glycyrrhizin
Study: 10574137
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg glycyrrhizin
Study: 10574137
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg glycyrrhizin
Study: 10574137
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg glycyrrhizin)
Study: 2063158
Drug: Penicillin-G 5
Normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin-G 5 million IU
Study: 6862724
Drug: Thioridazine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine (1.0 mg/kg body wt.)
Study: 6862724
Drug: Thioridazine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine (1.5 mg/kg body wt.)
Study: 6862724
Drug: Thioridazine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine (1.0 and 1.5 mg/kg body wt.)
Study: 31855102
Drug: Endometriosis Health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometriosis Health Profile-30 (EHP-30) intervention administered at day 1, month 3 (M3), and month 6 (M6).
Study: 20026818
Drug: Current intensity-modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current intensity-modulated radiation therapy (IMRT) protocol using the Pinnacle(3) planning system
Study: 12023504
Drug: Stress reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress reduction interventions (not specified if alone or in combination with pharmacotherapies targeting the HPA axis)
Study: 12023504
Drug: Drugs affecting
Normalized name: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs affecting the synthesis and/or secretion of corticosterone
Study: 12023504
Drug: Corticotropin-releasing hormone
Normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotropin-releasing hormone (CRH)
Study: 10463960
Drug: Budesonide 400
Normalized name: Budesonide 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 400 mg twice daily for two weeks
Study: 7751683
Drug: OPV containing
Normalized name: Opvee
DrugBank: Nalmefene (DB06230)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: OPV containing twice the standard potency of Sabin type 1 virus
Study: 7751683
Drug: Standard formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formulations of OPV
Study: 555487
Drug: Special behavior
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Special behavior therapy group
Study: 555487
Drug: Regular behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular behavior therapy group
Study: 27533472
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution (500 mL) before abdominal and pelvic CT; n = 2244 patients.
Study: 20919574
Drug: Reamberin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reamberin (400 ml/day for 10 days)
Study: 18842392
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of isoflavone
Study: 18842392
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of casein placebo
Study: 12050246
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (2 IU/m(2).d)
Study: 2031520
Drug: Cefoxitin, 2
Normalized name: CefOXitin, 2 g injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin, 2 gm intramuscular plus probenecid, 1 gm, followed by doxycycline, 100 mg twice daily for 10 days
Study: 6759242
Drug: Multiple subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple subcutaneous injections (MSI)
Study: 31552584
Drug: Hydrocortisone 20
Normalized name: hydrocortisone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 20 mg per day for 14 days
Study: 31552584
Drug: Prednisolone once
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone once daily for 14 days
Study: 25127178
Drug: Trauma-focused Exposure
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused Exposure Therapy (EXP)
Study: 19243606
Drug: KAb201 via
Normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAb201 via intravenous route at 50 mCi
Study: 3362274
Drug: sulindac 200
Normalized name: sulindac 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulindac 200 mg p.o. b.i.d.
Study: 3362274
Drug: indomethacin 25
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: indomethacin 25 mg p.o. t.i.d. and 100 mg p.r.
Study: 31149841
Drug: Cervicothoracic transcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervicothoracic transcutaneous electrical nerve stimulation (CTENS) - 30 min twice daily, 80-Hz frequency, 150-μs pulse duration for 14 days
Study: 16415316
Drug: BIS 40-50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS 40-50, effect site remifentanil concentration 1 ng ml(‐1)
Study: 16415316
Drug: BIS 40-50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS 40-50, remifentanil 2 ng ml(‐1)
Study: 16415316
Drug: BIS 40-50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS 40-50, remifentanil 4 ng ml(‐1)
Study: 16415316
Drug: BIS 25-35,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS 25-35, remifentanil 2 ng ml(‐1)
Study: 16415316
Drug: BIS 55-65,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS 55-65, remifentanil 2 ng ml(‐1)
Study: 15553107
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg intravenous orphenadrine citrate
Study: 11568514
Drug: 20 mg/1.73
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/1.73 m2
Study: 11568514
Drug: 40 mg/1.73
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/1.73 m2
Study: 9333107
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg/day for 28 days
Study: 9333107
Drug: Lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20 mg/day for 28 days
Study: 8408451
Drug: Dexamethasone (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1.5 mg) pretreatment
Study: 8408451
Drug: Haloperidol treatment
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol treatment (0.05 mg/kg, i.v.)
Study: 31651335
Drug: Rapael Smart
Normalized name: benzalkonium chloride Topical Foam [Smart San]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapael Smart Board™ (SB) with 30 min of intervention and 30 min of standard occupational therapy
Study: 31651335
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CON) with 60 min of conventional occupational therapy
Study: 29084736
Drug: Pioglitazone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (45 mg/d target dose)
Study: 21338804
Drug: High energy
Normalized name: High energy formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: High energy diet (OVR) - 1.62 Mcal of NE<sub>L</sub>/kg; 15% crude protein, ad libitum intake
Study: 21338804
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (CON) - 1.21 Mcal of NE<sub>L</sub>/kg; 14.2% crude protein, 100% NRC requirements
Study: 21338804
Drug: Restricted intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restricted intake diet (RES) - 1.62 Mcal of NE<sub>L</sub>/kg; 15% crude protein, 80% of energy requirements
Study: 17040006
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate (4.5, 6.0, or 9.0 g per day)
Study: 10627097
Drug: Self-reported drinking
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported drinking at treatment admission
Study: 10627097
Drug: Blood chemistry
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood chemistry values (liver function tests) at treatment admission
Study: 3592329
Drug: Intramuscular chlorpromazine
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular chlorpromazine (CPZ) 1 mg/kg
Study: 3592329
Drug: Intramuscular chlorpromazine
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular chlorpromazine (CPZ)
Study: 25491433
Drug: Mirabegron 50
Normalized name: mirabegron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 50 mg/day
Study: 18344738
Drug: PRX-00023 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRX-00023 (80 mg/d)
Study: 16797903
Drug: Resistance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance training plus vitamin D 400 IU plus 800 mg of calcium per day
Study: 11094584
Drug: Tramadol 100
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 100 mg (T1)
Study: 11094584
Drug: Tramadol 200
Normalized name: TRAMADOL 200MG (RYZOLT) SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 200 mg (T2)
Study: 8930424
Drug: valsartan 20
Normalized name: valsartan 20 MG in 5 mL Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 20 mg
Study: 8332965
Drug: Ticlopidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (2 x 250 mg daily) from the second preoperative day until the seventh postoperative day
Study: 3572208
Drug: Labetalol 200
Normalized name: HCTZ 25/LABETALOL 200MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 200 mg
Study: 3771472
Drug: Labetalol 200
Normalized name: HCTZ 25/LABETALOL 200MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 200 mg + Isoproterenol
Study: 3771472
Drug: Labetalol 400
Normalized name: labetalol 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 400 mg + Isoproterenol
Study: 3771472
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg + Isoproterenol
Study: 3771472
Drug: Metoprolol 200
Normalized name: metoprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 200 mg + Isoproterenol
Study: 29506504
Drug: Glycopyrronium MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium MDI 3.6 μg
Study: 29506504
Drug: Ipratropium MDI
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium MDI 34 μg
Study: 27255474
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (5mg daily for 12 months)
Study: 25022762
Drug: Whole blood
Normalized name: Whole blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole blood injection
Study: 25022762
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection with physical therapy alone
Study: 22886853
Drug: Low demand,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low demand, high basal infusion (LDHI) strategy
Study: 22886853
Drug: High demand,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High demand, low basal infusion (HDLI) strategy
Study: 10802492
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (INO) 20 ppm
Study: 9252000
Drug: Cervical spine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical spine manipulative physiotherapy treatment
Study: 1504055
Drug: Recombinant interleukin-2
Normalized name: Recombinant interleukin-2 human
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant interleukin-2 (rIL-2) administered as a 1- or 2-hour i.v. infusion, with doses of 12 x 10(6) IU/m2, 18 x 10(6) IU/m2, and 24 x 10(6) IU/m2, given every Monday/Wednesday/Friday for 3 weeks
Study: 6320226
Drug: delta 9‐tetrahydrocannabinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: delta 9‐tetrahydrocannabinol (THC) 17.5 mg orally
Study: 6320226
Drug: Nabilone 2
Normalized name: nabilone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone 2 mg orally
Study: 6320226
Drug: 1-g marihuana
Normalized name: Mariana Mariana Seed
DrugBank: Milk thistle (DB14375)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-g marihuana cigarette containing 1.83% THC, smoked
Study: 26077620
Drug: Face-to-Face Cognitive
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-Face Cognitive Behavioral Therapy (FtF‐CBT)
Study: 31509674
Drug: n-3 group
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 group (fish-oil capsules containing 900 mg of n-3 long-chain polyunsaturated fatty acids)
Study: 31509674
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (vegetable-oil capsules containing trace n-3 long-chain polyunsaturated fatty acids)
Study: 29038282
Drug: 33% daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 33% daily dosing under directly observed therapy (DOT)
Study: 29038282
Drug: 67% daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 67% daily dosing under directly observed therapy (DOT)
Study: 29038282
Drug: 100% daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% daily dosing under directly observed therapy (DOT)
Study: 27519769
Drug: Telmisartan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (20 mg/day) for 12 weeks
Study: 27519769
Drug: Telmisartan (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (30 mg/kg/day, orally) for 7 days
Study: 23238507
Drug: Intravenous metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoprolol infusion 1-3 mg per hour
Study: 23238507
Drug: Biatrial pacing
Normalized name: sotalol
DrugBank: Sotalol (DB00489)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biatrial pacing and oral metoprolol (50-150 mg daily for 72 hours)
Study: 23238507
Drug: Intravenous metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoprolol infusion
Study: 23238507
Drug: Biatrial pacing
Normalized name: sotalol
DrugBank: Sotalol (DB00489)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biatrial pacing and oral metoprolol